双重准G9a和DNMTs诱导多发性骨髓瘤中的抗瘤作用
Patrick William Nylund1, Berta Garrido-Zabala2, Stefania Iliana Tziola2
1The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Blood advances
|July 17, 2025
概括
针对G9a和DNA甲基转移酶 (DNMTs) 的双重表观遗传抑制显示出治疗多发性骨髓瘤 (MM) 的前景. 这种组合疗法有效地减少了瘤生长,并在临床前模型中抑制了关键基因.
科学领域:
- 血液学 血液学 血液学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 多发性骨髓瘤 (MM) 是一种具有挑战性的血细胞恶性瘤,治疗选择有限.
- 表观遗传失调,特别是涉及G9a和DNA甲基转移酶 (DNMTs),与MM病原和耐药性有关.
- 缺乏对G9a和DNMTs在MM进展中的相互作用的全面理解.
研究的目的:
- 研究G9a和DNMT在多发性骨髓瘤中的协同作用.
- 探索双G9a和DNMT抑制的潜力,作为MM的治疗策略.
主要方法:
- 使用针对G9a和DNMT的小分子抑制剂进行组合治疗.
- 进行了分子分析,包括H3K9me2分布,DNA甲基组和转录组概况.
- 在初级MM细胞,MM细胞系和体内临床前异种移植模型中评估治疗疗效.
主要成果:
- 确定了一种涉及G9a和DNMTs的基因沉默机制,可以抑制MM中的瘤抑制基因.
- 证明G9a和DNMTs的双抑制降低了MM细胞的活力,并诱导了细胞亡.
- 观察到瘤驱动因子 (IRF4,XBP1,MYC) 的表达减少和与亡相关的基因表达增加.
- 在体内表现出强大的瘤回归,使用G9a抑制剂A366和DNMT抑制剂Decitabine的组合.
结论:
- 在多发性骨髓瘤中,G9a和DNMT合作使关键的瘤抑制基因沉默.
- 联合抑制G9a和DNMTs代表了MM的有前途的治疗策略.
- 这种方法需要进一步研究MM治疗中的临床转化.
更多相关视频
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K